Stanford nixes industry-funded CME

The church-and-state separation of drugmakers and continuing medical education continues apace. Now it's Stanford's medical school that's refusing to take industry funding for specific CME programs or courses. The school won't accept money or in-kind help like equipment or supplies or services. Nor will it let for-profit CME companies that take industry money deliver their courses on campus.

Stanford joins a handful of other institutions that have curtailed their industry-funded CME recently. Memorial Sloan-Kettering cut itself off of industry funding for CME, the Wall Street Journal Health Blog reminds us, and Pfizer recently came at the problem from a different direction by saying it would no longer fund CME courses offered by for-profit companies.

What will Stanford accept? Well, it will take contributions to a pool of money that the university can then allocate as it sees fit. About half a dozen other med schools have created similar pools. It's an idea that could catch on; in fact, the CME accreditation body has been considering establishing a centralized pool for industry contributions. The money would be divvied up by medical societies.

- read the WSJ Health Blog post
- see the New York Times story

Suggested Articles

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

Hengrui's Sun Piaoyang is stepping down as chairman, but he'll retain control of the pharma major he's headed for 30 years—and made a fortune…